One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy;Az atorvastatin/amlodipin fix kombináció versus az atorvastatinterápia a terápiahu′ség tükrében

Orvosi Hetilap

Volumn 157, Issue 11, 2016, Pages 425-429

  Simonyi, Gábor ^a   Ferenci, Tamás ^b  

^a Szent Imre Egyetemi Oktatokorhaz Nephrologia Hypertonia Profil Es Aktiv Geriatria   (Hungary)

^b ÓBUDA UNIVERSITY   (Hungary)

Author keywords

Adherence; Atorvastatin amlodipin Fixed Dose Combination; Persistence; Targets

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; AMLODIPINE; AMLODIPINE, ATORVASTATIN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ARTICLE; DYSLIPIDEMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; SURVIVAL TIME; ADULT; AGED; BLOOD; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATORVASTATIN CALCIUM; BLOOD PRESSURE; CHOLESTEROL, LDL; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84960873982     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/650.2016.30401     Document Type: Article

References (22)

1. Kannel, W. B.: Risk stratification in hypertension: new insights from the Framingham Study. Am. J. Hypertens., 2000, 13(1 Pt 2), 3S-10S.
2. Papadopoulos, D. P., Papademetriou, V.: Resistant hypertension: diagnosis and management. J. Cardiovasc. Pharmacol. Ther., 2006, 11(2), 113-118.
3. Fields, L. E., Burt, V. L., Cutler, J. A., et al.: The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension, 2004, 44(4), 398-404.
4. Moser, M., Franklin, S. S.: Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J. Clin. Hypertens. (Greenwich), 2007, 9(5), 316-323.
5. Mozaffarian, D., Benjamin, E. J., Go, A. S., et al.: Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation, 2016, 133(4), e38-e360.
6. Kékes, E.: Prevalence of hypertension in Hungary based on the WHO's data 2014. [A hypertonia prevalenciája a világban és hazánkban a 2014-es WHO adatbázis alapján.] Hypertonia és Nephrologia, 2015, 19(6), 265-266. [Hungarian]
7. Kotseva, K., Wood, D., De Backer, G., et al., EUROASPIRE Study Group: EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur. J. Cardiovasc. Prev. Rehabil., 2009, 16(2), 121-137.
8. Kékes, E.: The importance of combined antihypertensive and antilipid therapy in general practices. [A kombinált antihypertensiv és antilipid kezelés a mindennapi gyakorlatban.] Hypertonia és Nephrologia, 2009, 13(1), 3-10. [Hungarian]
9. Kostis, J. B.: The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc. Drugs Ther., 2007, 21(4), 297-309.
10. Neaton, J. D., Wentworth, D.: Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall finding and differences by age for 316.099 white men. Arch. Intern. Med., 1992, 152(1), 56-64.
11. Emberson, J. R., Whincup, P. H., Morris, R. W., et al.: Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur. Heart J., 2003, 24(19), 1719-1726.
12. Mills, M.: Introducing survival and event history analysis. Sage Publications, London, 2011.
13. Willett, J. B., Singer, J. D.: Investigating onset, cessation, relapse, and recovery: why you should, and how you can, use discretetime survival analysis to examine event occurrence. J. Consult. Clin. Psychol., 1993, 61(6), 952-965.
14. Royston, P., Parmar, M. K.: Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med. Res. Methodol., 2013, 13, 152.
15. Patel, B. V., Leslie, R. S., Thiebaud, P., et al.: Adherence with single-pill amlodipine/atorvastatin vs two-pill regimen. Vasc. Health Risk Manag., 2008, 4(3), 673-681.
16. Simonyi, G., Ferenci, T.: Patient adherence with fixed doses combination of ezetimibe and simvastatin behind the results of IMPROVE-IT trial. [Az ezetimib/simvastatin fix kombináció és a terápiahu′ség az IMPROVE-IT vizsgálat hátterében.] Metabolizmus, 2015, 13(1), 64-71. [Hungarian]
17. Mason, R. P., Kubant, R., Heeba, G., et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res., 2008, 25(8), 1798-1806.
18. Sever, P. S., Chang, C. L., Gupta, A. K., et al.: The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur. Heart J., 2011, 32(20), 2525-2532.
19. Blank, R., LaSalle, J., Reeves, R., et al.: Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini Study). J. Clin. Hypertens. (Greenwich), 2005, 7(5), 264-273.
20. Preston, R. A., Harvey, P., Herfert, O., et al.: A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J. Clin. Pharmacol., 2007, 47(12), 1555-1569.
21. Neutel, J. M., Bestermann, W. H., Dyess, E. M., et al.: The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J. Clin. Hypertens. (Greenwich), 2009, 11(1), 22-30.
22. Kékes, E.: The success of fixed combined amlodipine/atorvastatin (Amlator®) therapy in patients with hypertension and dyslipidemia. [A fix kombinációban adott amlodipin/atorvastatin (Amlator ®) kezelés sikere dyslipidaemiás hypertoniás betegekben.] Hypertonia és Nephrologia, 2013, 17(1), 19-27. [Hungarian]